Auto Shanghai 2023 ushers in a new era of intelligent vehicles! Nearly 20 mass-produced models equipped with RoboSense LiDAR
28.4.2023 12:28:00 EEST | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, announced today its M series LiDAR products, which assisted more than 10 well-known global automakers showcase nearly 20 intelligent vehicle models at the 20th Shanghai International Automobile Industry Exhibition 2023 (referred to as the Auto Shanghai 2023), presenting the excellent performance of their intelligent driving assistance systems to the audience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230428005133/en/
Part of EV models equipped with RoboSense LiDAR showcased at Auto Shanghai 2023 (Photo: Business Wire)
This year's Shanghai Auto Show brought more than 1,000 exhibitors, including well-known global car companies, independent domestic car brands, new car-making forces, and automobile technology companies, using 13 indoor exhibition halls.
The M series sensors were the first LiDAR in the world to achieve automotive-grade mass production. It uses a patented revolutionary chip-based 2D scanning solution that boasts supreme performance and reliability.
According to the statistics obtained by industry media, “there are 38 models equipped with LiDARs at Auto Shanghai 2023, of which RoboSense is the biggest winner, being the LiDAR supplier of 18 of them”，the brands including SAIC IM, BYD, XPeng, FAW Hongqi, GWM WEY, Chery Exeed, Geely, GAC Hyper, Lotus, etc. To date, RoboSense has earned design wins for mass production of LiDAR products for over 50 vehicle models with 18 automakers.
As the theme of this auto show, "Embracing the New Era of the Automobile Industry," the global automobile industry is accelerating its transformation and upgrading towards electrification and intelligence. Against this backdrop, this year's Shanghai Auto Show is not only a concentrated display of product strength for the global automobile industry's intelligent transformation and upgrading, but also strong evidence of RoboSense's efforts to accelerate the intelligent development of the automobile industry.
RoboSense has invested heavily in building world-class product development and testing capabilities, while expanding its global footprint with operational headquarters in both Europe and the US. Its capabilities include intelligent manufacturing system in Southern China, along with the world’s first and only certified accreditation automotive-grade LiDAR laboratory, its China National Accreditation Service (CNAS) certified LiDAR lab, with more than 200 advanced pieces of testing equipment.
RoboSense's M series LiDAR technology has played a significant role in the intelligent transformation of the automobile industry, and the 2023 Shanghai Auto Show has demonstrated the excellent performance of intelligent driving assistance systems, showcasing the industry's progress towards electrification and intelligence.
About RoboSense (www.robosense.ai):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230428005133/en/
Contact information
Grace Ye
media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom